CTIM-20 - Prospective randomized phase II placebo-controlled trial of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE)

Friday, November 18, 2022

7:30 PM – 9:30 PM ET

Location: West/Central Hall

Poster Presenter(s)

Manmeet S. Ahluwalia, MD, MBA

Miami Cancer Institute, Baptist Health South Florida
Miami, United States

Author(s)

mC

michael J Ciesielski

Roswell Park
Buffalo, United States
AA

Ajay Abad, MD

Roswell Park
Buffalo, United States
David A. Reardon, MD

Dana-Farber Cancer Insitute
Boston, United States
RA

Robert Aiken, MD

Rutgers
new jersey, United States
MB

Marissa Barbaro

NYU Langone Health
New York, United States
KS

Kaylyn Sinicrope, MD

Norton Neuroscience Institute, Department of Neuro-Oncology
Louisville, United States
David M. Peereboom, MD

Cleveland Clinic Foundation
Cleveland, United States
Yazmin Odia, MD, MS

Miami Cancer Institute
Miami, United States
Andrew J. Brenner, MD.,Ph.D

UT Health San Antonio
San Antonio, United States
vv

vyshak venur

UW
seattle, United States
Ab

Ahmed belal

Roswell Park
Buffalo, United States
Jq

Jingxin qiu

Roswell Park
Buffalo, United States
AK

Atulya A. Khosla, MD

Miami Cancer Institute, Baptist Health South Florida
Miami, United States
cs

cathy schilero

Cleveland Clinic
Cleveland, United States
dc

danielle casucci

Mimivax
Buffalo, United States
lm

laszlo mechtler

Roswell Park
Buffalo, United States
RF

Robert A. Fenstermaker, MD

Roswell Park
Buffalo, United States

Background: Newly diagnosed glioblastoma (nGBM) has a dismal prognosis with survival of 15-18 months. Tumor associated “survivin” protein is expressed in >95% of nGBM and is targetable with the use of SurVaxM, shown to be effective at generating cytotoxic T lymphocytes.

Methods: nGBM patients are being enrolled in this randomized placebo-controlled trial phase II study. Eligibility Criteria includes age ≥ 18, KPS ≥ 70, IHC confirmed survivin-expression, and residual contrast enhancement of ≤1 cm³ by MRI, within 72 hours of surgical resection. Patients are randomized 3:2 into two arms A:B to treatment with SurVaxM in emulsion with Montanide plus sargramostim (local injection) and standard-of-care TMZ (Arm A), or placebo (saline in emulsion with Montanide) plus saline (local injection) and standard-of-care TMZ (Arm B). There are three active treatment phases in the study with vaccine priming (VP) phase; adjuvant TMZ phase; and Vaccine Maintenance (VM) phase. A total of four (4) priming doses of SurVaxM in Montanide plus sargramostim (“SurVaxM/sargramostim”) or placebo in Montanide/saline (“Placebo/Placebo”) will be administered every two weeks ( ± 3 days) during the priming phase, with subsequent dosing every 8 weeks ( ± 1 week) during the vaccine maintenance phase. After priming doses, SurVaxM/sargramostim or Placebo/Placebo will be administered every 8 weeks ( ± 1 week) until tumor progression or for a maximum of 24 months. The total sample size is of 265 patients, with 159 patients in the SurVaxM arm and 106 patients in the control arm. The primary objective is to determine the overall survival (OS), and the secondary objectives include progression-free survival (PFS), OS at pre-specified time points (OS-15, OS-18 and OS-24), PFS at pre-specified time points (PFS-3, PFS-6 and PFS-12) and evaluation of toxicities. Study duration is expected at 36 months, with enrollment ongoing at several centers and planned for total of 20 participating centers.